Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Paul Hartmann AGFRA:PHH2 +0.75%64 EV-to-EBITDA is 3.34 as of Aug. 28, 2026, which is 35% below its 10-year median of 5.15. GuruFocus rates FRA:PHH2 with a GF Score™ of 64/100 and a GF Value™ of €226.94 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 523 Medical Devices & Instruments companies, Paul Hartmann AG ranks better than 91.59% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Paul Hartmann AG's enterprise value is €956 Mil.
Paul Hartmann AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €286 Mil. Therefore, Paul Hartmann AG's EV-to-EBITDA for today is 3.34.
The historical rank and industry rank for Paul Hartmann AG's EV-to-EBITDA or its related term are showing as below:
FRA:PHH2'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.01 Med: 5.15 Max: 7.5
Current: 3.34
During the past 13 years, the highest EV-to-EBITDA of Paul Hartmann AG was 7.50. The lowest was 3.01. And the median was 5.15.
FRA:PHH2's EV-to-EBITDA is ranked better than 91.59% of 523
companies
in the Medical Devices & Instruments industry
Industry Median: 14.62
vs FRA:PHH2: 3.34
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Paul Hartmann AG (FRA:PHH2) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Paul Hartmann AG's PE Ratio (TTM) for today is calculated as:
Paul Hartmann AG's share price for today is €201.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Paul Hartmann AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €28.120.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Paul Hartmann AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PHH2 vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Paul Hartmann AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paul Hartmann AG EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Paul Hartmann AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Paul Hartmann AG's EV-to-EBITDA falls into.
Paul Hartmann AG's current Enterprise Value is €956 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Paul Hartmann AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €286 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paul Hartmann AG (FRA:PHH2) has a EV-to-EBITDA of 3.34 as of Aug. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Paul Hartmann AG. This is 35% below median its historical median of 5.15. Over the past decade, Paul Hartmann AG's EV-to-EBITDA has ranged from 3.01 to 7.50. According to the industry distribution chart, Paul Hartmann AG ranks #44 out of 523 companies in the Medical Devices & Instruments industry, placing it in the top 8.4%.
Is Paul Hartmann AG's EV-to-EBITDA too high?
Paul Hartmann AG's current EV-to-EBITDA of 3.34 is 35% below median its 10-year median of 5.15. Over the past 10 years, this metric has ranged from a low of 3.01 to a high of 7.50. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.62. Paul Hartmann AG's value of 3.34 is 77.2% below this industry median. Based on the distribution chart, Paul Hartmann AG ranks #44 out of 523 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Paul Hartmann AG has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Paul Hartmann AG's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Paul Hartmann AG ranks #44 out of 523 companies for EV-to-EBITDA. This places Paul Hartmann AG in the top 8% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 14.62. Paul Hartmann AG's value of 3.34 is 77.2% below this benchmark. Historically, Paul Hartmann AG's own EV-to-EBITDA has ranged from 3.01 to 7.50 over the past decade. While the company's 10-year median is 5.15 vs. the industry median of 14.62, Paul Hartmann AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.62, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paul Hartmann AG's current EV-to-EBITDA of 3.34 is 77.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Paul Hartmann AG. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paul Hartmann AG's current EV-to-EBITDA is 3.34, which is 35% below median its own 10-year median of 5.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paul Hartmann AG stock overvalued right now?
Based on GuruFocus' analysis, Paul Hartmann AG (FRA:PHH2) is currently considered Modestly Undervalued. The stock's GF Value™ is €226.94, compared to a current price of €201.00 — trading 11.4% below its estimated fair value. The current EV-to-EBITDA is 3.34, which is 35% below median its 10-year median of 5.15 and 77.2% below the Medical Devices & Instruments industry median of 14.62. Paul Hartmann AG's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Paul Hartmann AG (FRA:PHH2), the current EV-to-EBITDA is 3.34 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paul Hartmann AG (FRA:PHH2) Overvalued in 2026?
Based on GuruFocus' analysis, Paul Hartmann AG stock appears to be undervalued.
The current stock price of €201.00 is trading 11.4% below its estimated GF Value™ of €226.94.
GuruFocus considers Paul Hartmann AG to be Modestly Undervalued.
Key valuation signals for FRA:PHH2:
EV-to-EBITDA: 3.34 (35% below median its 10-year median of 5.15)
GF Value™: €226.94 vs. price of €201.00 (11.4% below fair value)
Industry Position: 77.2% below the Medical Devices & Instruments median (#44 of 523)
No single metric tells the full story. See the FRA:PHH2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paul Hartmann AG engages in the production of medical and hygiene products. It operates through Wound Management, Incontinence Management and Infection Management and other segments. The Wound segment comprises wound dressing and treatment, compression therapy, first aid, immobilization, and diagnostics. The Incontinence segment provides incontinence hygiene, patient care, and medical skin care. The Infection segment consists of custom procedure trays, surgical draping systems, disposable surgical instruments, and disinfectants. The Other activities include activities in cotton-wool products, medical consumer goods and pharmaceutical products and others. All the activities are functioned through the region of US and derive revenue through the sale of medical and hygiene products.
64GF Score
Get the complete analysis for FRA:PHH2
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHH2 has been successfully added to your 
